Fresenius

Some brighter views

21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."

PDF page sample
Pages
54
Language
English
Published on
21/06/22
Download
You may also be interested by these reports :
11/09/26
MedTech sector momentum has finally turned constructive in recent weeks, a welcome change after a multi-year stretch of post-covid destocking, supply ...
08/09/26
Medtech soared after Covid, then dropped out of sight until May 2026. Are its five lean years finally over? MedTech may have found a bottom Covid-era ...
07/09/26
We have revised our estimates upwards and removed the 20% discount previously applied to the peer-based valuation. This optimism is supported by ...
04/09/26
Bastide ended FY25/26 above its revenue target, with Q4 organic growth recovering as the VPH headwind faded, confirming the one-off nature of the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO